Login / Signup

Bioresorbable Vascular Scaffold Korean Expert Panel Report.

Jung Min AhnDuk Woo ParkSung Jin HongYoung Keun AhnJoo-Yong HahnWon Jang KimSoon Jun HongChang Wook NamDo Yoon KangSeung Yul LeeWoo Jung ChunJung Ho HeoDeok Kyu ChoJin Won KimSung Ho HerSang Wook KimSang Yong YooMeyong-Ki HongSeung Jea TahkKee Sik KimMoo Hyun KimYang Soo JangSeung Jung Park
Published in: Korean circulation journal (2017)
Bioresorbable vascular scaffold (BRS) is an innovative device that provides structural support and drug release to prevent early recoil or restenosis, and then degrades into nontoxic compounds to avoid late complications related with metallic drug-eluting stents (DESs). BRS has several putative advantages. However, recent randomized trials and registry studies raised clinical concerns about the safety and efficacy of first generation BRS. In addition, the general guidance for the optimal practice with BRS has not been suggested due to limited long-term clinical data in Korea. To address the safety and efficacy of BRS, we reviewed the clinical evidence of BRS implantation, and suggested the appropriate criteria for patient and lesion selection, scaffold implantation technique, and management.
Keyphrases
  • drug release
  • tissue engineering
  • emergency department
  • electronic health record
  • machine learning
  • quality improvement